March 14, 2015 – San Diego – The landmark trial of cardiovascular arena PROMISE TRIAL was the limelight of ACC conference 2015 where the trial results were presented for the first time. The trial was important because a large scale research study had never been conducted before to compare different cardiac imaging modalities.
North Dallas Research Associates played a leading role to conduct this trial and was amongst the top 5 highly performed sites by enrolling 410 patients. Secondary to this extraordinary contribution in the trial, our Principal Investigator Dr. M. Akram Khan was nominated as the co-author for the Manuscript published in the New England Journal of Medicine.
The primary goal of the PROMISE study was to compare the clinical outcomes in a scenario where coronary CTA was performed ahead of traditional stress test to rule out significant coronary artery disease in patients who presented with symptoms of chest pain / SOB.
This keenly anticipated trial confirmed what many cardiologists and radiologists have long suspected to be true that coronary CTA is far more effective in accurately diagnosing patients with low to moderate chest pain.
According to Dr Khan, interventional cardiologist and co author of the study manuscript, “PROMISE trial results brought a paradigm shift in the current cardiology practice that will eventually lead us to a lower radiation exposure and cost reduction for our patients.”
Society of Cardiovascular Computed Tomographic President Ricardo C. Cury MD FSCCT observed that these findings demonstrate that coronary CTA plays a critical role in enabling physicians to determine and plan the best course of action in treating the millions of persons annually who present with low to moderate chest pain.
“Unlike most trials where medical care is very tightly controlled, this study was designed to represent real world care. The health centers that collected the data were responsible for interpreting the tests and doing appropriate patient follow-up. Because this was such a community-based, real-world setting, the study really tells us a lot about clinical practice and ho patients are being cared for in the U.S. now.” said Pamela Douglas, study’s lead author.
The study was funded by the National Heart, Lung and Blood Institute of the National Institute of Health (NIH).